Preoperative CA 15‐3 concentrations predict outcome of patients with breast carcinoma

CA 15‐3 is a breast‐associated mucin that is elevated in the majority of breast carcinoma patients with distant metastases. Currently, the main application of this marker is in monitoring and detecting recurrences in patients with diagnosed breast carcinoma.

[1]  O. Nilsson,et al.  Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.

[2]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[3]  M. Kerin,et al.  An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. , 1995, British Journal of Cancer.

[4]  J. Gopas,et al.  CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. , 1995, Israel journal of medical sciences.

[5]  M. Duffy,et al.  The clinical value of CEA and CA 15-3 in breast cancer management , 1995, The International journal of biological markers.

[6]  M. Bolzan,et al.  CA 15-3 value and neoplastic disease predictivity in the follow-up for breast cancer. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[7]  J. Geraghty,et al.  CA 15‐3 in patients with locoregional and metastatic breast carcinoma , 1992, Cancer.

[8]  A. Cuschieri,et al.  Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. , 1991, Journal of the Royal College of Surgeons of Edinburgh.

[9]  F. Caponigro,et al.  Impact of Preoperative CA 15-3 Levels in Operable Breast Cancer. Comparison with Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA) , 1991, The International journal of biological markers.

[10]  M. Kerin,et al.  CA15‐3: Its relationship to clinical stage and progression to metastatic disease in breast cancer , 1989, The British journal of surgery.

[11]  Mark R. Segal,et al.  Regression Trees for Censored Data , 1988 .

[12]  D. Pons-Anicet,et al.  Value of CA 15:3 in the follow-up of breast cancer patients. , 1987, British Journal of Cancer.

[13]  Á. Ruibal,et al.  Circulating Ca 15.3 Levels in Breast Cancer. Our Present Experience , 1986, The International journal of biological markers.

[14]  D. Hayes,et al.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. , 1985, The Journal of clinical investigation.

[15]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  D.,et al.  Regression Models and Life-Tables , 2022 .